New Bacteria-Based therapy tested for leukemia relapse prevention

NCT ID NCT07573111

Recruiting now Disease control Sponsor: Laguna Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only 12 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QUAIL-100 (a live, weakened bacteria given as a therapeutic)
What this could lead to: If it works, this could point toward a new way to help prevent relapse in high-risk leukemia patients after a stem cell transplant.
What could go wrong: This is a very early, first-in-human trial with only 12 participants, so safety and effectiveness are unknown. There is a risk of serious side effects, including graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute myeloid leukemia leukemia myelodysplastic syndrome Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Lucille Packard Children's Hospital of Stanford University
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.